NHLBI ICTR Video released on Single Arm Trials

On October 29, 2018, Berry Consultants proudly released the first in a series of short videos undertaken in our role as the Innovative Clinical Trials Resource (ICTR) for the National Institute of Health's National Heart, Lung, and Blood Institute (NHLBI). Our own Dr. Anna McGlothlin presented an engaging overview of the rationale and considerations related to single arm clinical trials. 

Single arm studies are used to conserve resources and facilitate enrollment, particularly in rare diseases, where the available number of participants is limited.  Potential participants, often reticent to be assigned placebo, are more likely to enroll when guaranteed access to a novel therapy.  Without a control, single arm trials immediately save 50% of the required patient resources compared to a standard randomized controlled trial.  While simple in concept, single arm trials pose challenges in interpretation and generalization, particularly due the uncertainty about how the control arm might have behaved.  In this short video Dr. Anna McGlothlin discusses these trade-offs and introduce possible innovative alternatives to single arm studies, such as statistical borrowing of historical information in a randomized study.

You may view the video here.  We encourage readers to access all of the resources available on the ICTR website, available at https://innovativeclinicaltrial.org and to register for an account to receive alerts when new materials are listed. We also welcome comments and questions and may use these in future blogs posts!

More Recent News

February 2024 QUOTES Webinar

Berry Consultants will be hosting a webinar on the optimization of a clinical trial design by estimating its impact on the expected net present value of a drug development program using the software QUOTES (Quantification and Optimization of Trial Expectations Simulator).

Blog: Precision Promise Adaptive Platform Trial update

Blog by: Kert Viele News from the Precision Promise platform trial. https://fibrogen.gcs-web.com/news-releases/news-release-details/fibrogen-announces-completion-pamrevlumab-arm-precision-promise Precision Promise is an adaptive platform trial investigating potential therapies for pancreatic cancer,

January 2024 FACTS Webinar

The Berry Consultants software team will be hosting its January FACTS webinar next Friday, January 19th at 11am EST to present the development plans for adding an ordinal endpoint option to the trial simulator.

Blog: Comments on the draft FDA master protocol guidance

Blog by: Kert Viele The FDA draft master protocol guidance is out https://www.fda.gov/regulatory-information/search-fda-guidance-documents/master-protocols-drug-and-biological-product-development Comments are due by February 22. Here are some preliminary thoughts and